BioHarvest Sciences Income from Continuous Operations 2020-2024 | BHST

BioHarvest Sciences income from continuous operations from 2020 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
BioHarvest Sciences Annual Income from Continuous Operations
(Millions of US $)
2023 $-13
2022 $-11
2021 $-10
2020 $-7
2019 $-5
2019 $-5
2018 $-5
BioHarvest Sciences Quarterly Income from Continuous Operations
(Millions of US $)
2024-06-30 $-1
2024-03-31 $-7
2023-12-31 $-7
2023-09-30 $-2
2023-06-30 $-3
2023-03-31 $-1
2022-12-31 $-3
2022-09-30 $-4
2022-06-30 $-2
2022-03-31 $-2
2021-12-31 $-2
2021-09-30 $-3
2021-06-30 $2
2021-03-31 $-7
2020-12-31 $-3
2020-09-30 $-2
2020-06-30 $-1
2020-03-31 $-0
2019-12-31
2019-09-30 $-1
2019-06-30 $-1
2019-03-31
Sector Industry Market Cap Revenue
Medical MED-BIOMED/GENE $0.098B $0.013B
BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Primo Water (PRMB) United States $4.535B 35.81
P.A.M Transportation Services (PAMT) United States $0.430B 0.00
Rigetti Computing (RGTI) United States $0.325B 0.00
Alpha Cognition (ACOG) Canada $0.035B 0.00
Atlantic Coastal Acquisition II (ABP) United States $0.000B 0.00